Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5004 in hepatic impairment
NCT06813781Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elecoglipron (4 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity, Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration and 1 more. Started Dec 2024; status: completed.
02
Drugs
elecoglipron
Beyond the preview
Go deeper on NCT06813781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06813781.